Apellis Pharmaceuticals (NASDAQ:APLS) Releases Quarterly Earnings Results

Apellis Pharmaceuticals (NASDAQ:APLSGet Free Report) issued its quarterly earnings results on Tuesday. The company reported ($0.73) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.73), Briefing.com reports. The business had revenue of $146.38 million for the quarter, compared to the consensus estimate of $143.34 million. Apellis Pharmaceuticals had a negative return on equity of 160.27% and a negative net margin of 133.34%. The business’s quarterly revenue was up 545.9% on a year-over-year basis. During the same period in the prior year, the firm posted ($1.50) earnings per share.

Apellis Pharmaceuticals Stock Down 1.0 %

Shares of NASDAQ:APLS traded down $0.66 during trading on Thursday, hitting $63.39. The company’s stock had a trading volume of 398,881 shares, compared to its average volume of 1,661,882. The business has a 50 day moving average price of $65.25 and a two-hundred day moving average price of $52.91. The company has a market capitalization of $7.51 billion, a PE ratio of -14.21 and a beta of 0.93. The company has a debt-to-equity ratio of 0.40, a quick ratio of 3.76 and a current ratio of 4.29. Apellis Pharmaceuticals has a fifty-two week low of $19.83 and a fifty-two week high of $94.75.

Analyst Upgrades and Downgrades

APLS has been the topic of several research reports. The Goldman Sachs Group upped their target price on Apellis Pharmaceuticals from $65.00 to $90.00 and gave the company a “buy” rating in a research report on Tuesday, January 9th. Robert W. Baird reaffirmed an “outperform” rating and set a $81.00 price target on shares of Apellis Pharmaceuticals in a research report on Tuesday, February 6th. Wedbush increased their price target on Apellis Pharmaceuticals from $60.00 to $67.00 and gave the stock a “neutral” rating in a research report on Wednesday. Wells Fargo & Company downgraded Apellis Pharmaceuticals from an “overweight” rating to an “equal weight” rating and cut their price target for the stock from $67.00 to $54.00 in a research report on Thursday, December 14th. Finally, Jefferies Financial Group raised Apellis Pharmaceuticals from a “hold” rating to a “buy” rating and increased their price target for the stock from $68.00 to $80.00 in a research report on Monday, February 5th. Three research analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $76.40.

Check Out Our Latest Stock Report on APLS

Insiders Place Their Bets

In related news, General Counsel David O. Watson sold 781 shares of the business’s stock in a transaction on Monday, February 12th. The shares were sold at an average price of $67.77, for a total transaction of $52,928.37. Following the completion of the transaction, the general counsel now owns 103,390 shares in the company, valued at $7,006,740.30. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. In other news, insider Lukas Scheibler sold 10,000 shares of the company’s stock in a transaction dated Friday, December 1st. The shares were sold at an average price of $60.00, for a total value of $600,000.00. Following the completion of the sale, the insider now directly owns 68,299 shares of the company’s stock, valued at $4,097,940. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, General Counsel David O. Watson sold 781 shares of the company’s stock in a transaction dated Monday, February 12th. The shares were sold at an average price of $67.77, for a total transaction of $52,928.37. Following the completion of the sale, the general counsel now directly owns 103,390 shares of the company’s stock, valued at $7,006,740.30. The disclosure for this sale can be found here. Insiders sold a total of 69,898 shares of company stock worth $4,493,552 over the last 90 days. Corporate insiders own 7.50% of the company’s stock.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in APLS. FIL Ltd acquired a new position in Apellis Pharmaceuticals during the fourth quarter worth about $340,000. Public Employees Retirement System of Ohio grew its position in Apellis Pharmaceuticals by 4.2% during the fourth quarter. Public Employees Retirement System of Ohio now owns 42,322 shares of the company’s stock worth $2,533,000 after buying an additional 1,700 shares during the period. Exome Asset Management LLC acquired a new position in Apellis Pharmaceuticals during the fourth quarter worth about $434,000. Virtus ETF Advisers LLC grew its position in Apellis Pharmaceuticals by 89.4% during the fourth quarter. Virtus ETF Advisers LLC now owns 6,251 shares of the company’s stock worth $374,000 after buying an additional 2,950 shares during the period. Finally, Legal & General Group Plc grew its position in shares of Apellis Pharmaceuticals by 2.1% in the fourth quarter. Legal & General Group Plc now owns 83,471 shares of the company’s stock valued at $4,997,000 after purchasing an additional 1,693 shares during the last quarter. 90.43% of the stock is owned by hedge funds and other institutional investors.

About Apellis Pharmaceuticals

(Get Free Report)

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, cold agglutinin disease, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, amyotrophic lateral sclerosis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy (GA).

Featured Stories

Earnings History for Apellis Pharmaceuticals (NASDAQ:APLS)

Receive News & Ratings for Apellis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Apellis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.